Unicycive Therapeutics (UNCY) Institutional Ownership $4.34 +0.02 (+0.53%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Unicycive Therapeutics (NASDAQ:UNCY)CurrentInstitutional OwnershipPercentage40.42%Number ofInstitutional Buyers(last 12 months)13TotalInstitutional Inflows(last 12 months)$192.33MNumber ofInstitutional Sellers(last 12 months)9TotalInstitutional Outflows(last 12 months)$172.69M Get UNCY Insider Trade Alerts Want to know when executives and insiders are buying or selling Unicycive Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data UNCY Institutional Buying and Selling by Quarter Unicycive Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Octagon Capital Advisors LP1,000,000$4.77M1.0%-90.0%7.911% 8/15/2025 Lazard Asset Management LLC11,575$55K0.0%N/A0.092% 8/14/2025 Nantahala Capital Management LLC939,202$4.56M0.2%-90.0%7.430% 8/14/2025 Acuta Capital Partners LLC62,899$300K0.4%-97.3%0.498% 8/14/2025 Vivo Capital LLC1,137,015$5.42M0.6%-90.0%8.995% 8/12/2025 JPMorgan Chase & Co.21,709$104K0.0%+11,698.4%0.172% 8/8/2025 Geode Capital Management LLC58,786$280K0.0%-89.9%0.465% 5/15/2025 Nantahala Capital Management LLC9,391,994$5.40M0.2%-9.6%7.786% 5/14/2025 Walleye Capital LLC4,094,256$2.35M0.0%-18.1%3.394% 5/12/2025 Vivo Capital LLC11,370,152$6.54M0.9%+14.0%9.426% Get the Latest News and Ratings for UNCY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/8/2025 XTX Topco Ltd123,233$71K0.0%-28.1%0.103% 2/17/2025 Octagon Capital Advisors LP10,000,000$7.94M1.3%+16.8%9.634% 2/17/2025 Alyeska Investment Group L.P.1,750,000$1.39M0.0%-22.2%1.686% 2/17/2025 Acuta Capital Partners LLC2,303,000$1.83M1.8%+16.4%2.219% 2/14/2025 Nantahala Capital Management LLC10,391,994$8.25M0.4%+268.5%10.012% 2/14/2025 Northern Trust Corp58,181$46K0.0%+142.4%0.056% 2/14/2025 Silverarc Capital Management LLC2,486,709$1.98M0.4%-37.8%2.396% 2/14/2025 Vivo Capital LLC9,970,152$7.92M0.9%+123.0%9.605% 2/13/2025 XTX Topco Ltd171,463$136K0.0%+142.2%0.165% 2/12/2025 Geode Capital Management LLC524,487$417K0.0%+30.3%0.505% 11/20/2024 Virtu Financial LLC73,975$30K0.0%+566.8%0.071% 11/15/2024 XTX Topco Ltd70,784$29K0.0%N/A0.075% 11/14/2024 Walleye Capital LLC5,000,000$2.04M0.0%N/A5.299% 11/14/2024 Acuta Capital Partners LLC1,979,199$807K0.7%N/A2.097% 11/13/2024 Great Point Partners LLC8,559,000$3.49M1.0%N/A9.071% 10/16/2024 Bleakley Financial Group LLC80,000$33K0.0%N/A0.085% 8/20/2024 Nantahala Capital Management LLC2,820,358$1.41M0.1%-15.4%7.499% 7/12/2024 Rosalind Advisors Inc.1,571,200$787K0.6%-16.4%4.178% 5/20/2024 Virtu Financial LLC26,082$36K0.0%N/A0.069% 5/16/2024 BVF Inc. IL3,611,601$4.98M0.1%+70.5%9.603% 4/25/2024 Rosalind Advisors Inc.1,879,646$2.59M2.4%N/A5.407% 2/15/2024 BVF Inc. IL2,118,139$1.84M0.0%-37.9%6.095% 11/15/2023 RA Capital Management L.P.3,470,688$2.99M0.1%N/A9.987% 11/8/2023 Vivo Capital LLC3,470,152$2.98M0.4%N/A9.986% 8/10/2023 Ground Swell Capital LLC20,001$26K0.1%N/A0.131% 4/26/2023 Oxbow Advisors LLC11,861$25K0.0%N/A0.078% 2/15/2023 Nantahala Capital Management LLC647,416$350K0.0%-8.9%4.302% 11/15/2022 Board of Trustees of The Leland Stanford Junior University63,019$37K0.0%-74.5%0.419% 11/10/2022 Nantahala Capital Management LLC710,542$419K0.0%-2.6%4.721% 8/15/2022 Nantahala Capital Management LLC729,680$606K0.0%+13.9%4.855% 4/22/2022 Truist Financial Corp37,462$48K0.0%N/A0.250% 11/12/2021 Board of Trustees of The Leland Stanford Junior University247,583$700K0.1%N/A1.707% 11/9/2021BlackRock Inc.11,443$33K0.0%N/A0.079% 10/28/2021 Tandem Capital Management Corp ADV15,500$44K0.0%N/A0.107% (Data available from 1/1/2016 forward) UNCY Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of UNCY shares? During the previous two years, 18 institutional investors and hedge funds held shares of Unicycive Therapeutics. The most heavily invested institutionals were Vivo Capital LLC ($5.42M), BVF Inc. IL ($4.98M), Octagon Capital Advisors LP ($4.77M), Nantahala Capital Management LLC ($4.56M), Great Point Partners LLC ($3.49M), RA Capital Management L.P. ($2.99M), and Walleye Capital LLC ($2.35M).Learn more on Unicycive Therapeutics' institutional investors. What percentage of Unicycive Therapeutics' stock is owned by institutional investors? 40.42% of Unicycive Therapeutics' stock is owned by institutional investors. Learn more on UNCY's institutional investor holdings. Which institutional investors have been buying Unicycive Therapeutics' stock? Of the 16 institutional investors that purchased Unicycive Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Vivo Capital LLC ($10.37M), Great Point Partners LLC ($8.56M), Nantahala Capital Management LLC ($7.57M), Walleye Capital LLC ($5M), RA Capital Management L.P. ($3.47M), Acuta Capital Partners LLC ($2.30M), and Rosalind Advisors Inc. ($1.88M). How much institutional buying is happening at Unicycive Therapeutics? Institutional investors have bought a total of 32,278,352 shares in the last 24 months. This purchase volume represents approximately $192.33M in transactions. Which of Unicycive Therapeutics' major shareholders have been selling company stock? Of the 9 institutional investors that sold Unicycive Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Vivo Capital LLC ($10.23M), Nantahala Capital Management LLC ($9.45M), Octagon Capital Advisors LP ($9M), Acuta Capital Partners LLC ($2.29M), Silverarc Capital Management LLC ($1.51M), Walleye Capital LLC ($905.74K), and Geode Capital Management LLC ($520.42K). How much institutional selling is happening at Unicycive Therapeutics? Institutional investors have sold a total of 34,463,598 shares in the last 24 months. This volume of shares sold represents approximately $172.69M in transactions. Related Companies Ocugen Major Shareholders Cartesian Therapeutics Major Shareholders Atea Pharmaceuticals Major Shareholders Neurogene Major Shareholders Lifecore Biomedical Major Shareholders Aurora Cannabis Major Shareholders Contineum Therapeutics Major Shareholders DBV Technologies Major Shareholders Mereo BioPharma Group Major Shareholders Jade Biosciences Major Shareholders This page (NASDAQ:UNCY) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
